What are your top takeaways from ACC 2023?

My “top 3” takeaways from ACC23 are;

1. CLEAR Outcomes trial which demonstrated that bempedoic acid reduced LDL by about 20% and improves long-term CV outcomes compared with placebo among patients with established ASCVD or high risk for it, and intolerance to statin therapy (though a minority of patien...

The main trials I would say:

• IVUS-guided intervention vs Angiography
• Anticoagulation and COVID
• Exercise and Cardiomyopathy

3 major trials in structural heart disease were presented at ACC:

1. TRILUMINATE RCT of medical therapy vs transcatheter edge-to-edge repair in patients with severe symptomatic tricuspid regurgitation. A key finding is that transcatheter repair was (a) effective in reducing tricuspid regurgitation (87%...